Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: This prospective study aimed to investigate estrogen-induced carcinogenesis by assessing the background levels of abasic sites (apurinic/apyrimidinic sites, AP sites) in Taiwanese breast cancer patients following 5 years of postoperative treatment without recurrence (5-year survivors) (n = 70). The study also sought to compare the extent of these DNA lesions with those found in healthy controls and in breast cancer patients prior to treatment.

Methods: Abasic sites were measured using an aldehyde reactive probe and quantified as the total number of abasic sites per total nucleotides. Characterization of the abasic sites in subjects recruited for this study was conducted using the abasic site cleavage assay using putrescine or T7 exonuclease (T7 Exo) and/or exonuclease III (Exo III).

Results: The number of abasic sites detected in 5 year survivors (26.7 ± 10.2 per 10 total nucleotides, n = 70) was significantly reduced by 46.9% compared to those in breast cancer patients before treatment (50.3 ± 59.2 per 10 total nucleotides, < 0.001), and was similar to the levels observed in healthy controls (23.3 ± 13.5 per 10 total nucleotides, > 0.05). Further investigation into the specific types of abasic sites indicated that the number of abasic sites excisable by putrescine in controls, breast cancer patients, and 5-year survivors were 63.3%, 78.6%, and 67.7%, respectively. These findings suggest the involvement of oxidative stress rather than depurination/depyrimidination of DNA adducts in the formation of abasic sites. Further analyses were performed using exonuclease cleavage assay to characterize the specific types of abasic sites including 5'-cleaved, 3'-cleaved, intact, and residual abasic sites. Results demonstrated that the proportion of residual abasic sites detected in controls, breast cancer patients, and 5-year survivors were estimated to be 32.7%, 48.8%, and 34.0%, respectively.

Conclusion: Overall, these findings suggest clear evidence of treatment-related effects on the reduction of levels of abasic sites as well as on the profile of abasic sites in 5 year survivors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550507PMC
http://dx.doi.org/10.1177/10732748241300656DOI Listing

Publication Analysis

Top Keywords

abasic sites
56
breast cancer
24
cancer patients
24
sites
16
total nucleotides
16
abasic
14
5-year survivors
12
controls breast
12
number abasic
12
postoperative treatment
8

Similar Publications

Many recent lines of evidence from the human microbiome and other fields indicate bacterial involvement in various types of cancer. has been recognized as the major cause of stomach cancer (gastric cancer), but the mechanism by which it destabilizes the human genome to cause cancer remains unclear. Our recent studies have identified a unique family of toxic restriction enzymes that excise a base (: adenine) from their recognition sequence (5'-GTC).

View Article and Find Full Text PDF

Apurinic/apyrimidinic (AP) sites in DNA can give rise to interstrand cross-links via reactions of the ring-opened AP-aldehyde residue with the exocyclic amino groups of 2'-deoxyadenosine, 2'-deoxyguanosine, and 2'-deoxycytosine residues (dA, dG, and dC) on the opposing strand to give imine/N-glycosylamine linkages. Endogenous AP-derived cross-links in cellular DNA could contribute to cancer, aging, and neurodegeneration. The yields of AP-derived cross-links produced by the various nucleobases vary widely, and, until now, it remained unclear whether these differences might simply reflect differences in the inherent reactivities of the nucleobases.

View Article and Find Full Text PDF

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are clinically effective in homologous recombination (HR)-deficient cancers but have limited efficacy in HR-proficient cancers; therefore, new strategies are needed to address this therapeutic limitation. Since PARP1 recognizes abasic sites as intermediates to repair single-strand breaks (SSBs) in the base excision repair (BER) pathway, we demonstrate that targeting these DNA abasic sites with a fused-quinoxaline-diazepine amine derivative () can enhance the effectiveness of the PARPi Olaparib in HR-proficient cancer cells (MDA-MB-231, HeLa, and SKOV3). cleaves abasic sites via β- and β,δ-elimination mechanisms, generating unusable substrates for DNA polymerase β, such as 3'-α,βunsaturated aldehyde and 3'-phosphate products, thereby disrupting the BER pathway and leading to the accumulation of SSBs.

View Article and Find Full Text PDF

Mitochondria-Targeting Abasic Site-Reactive Probe (mTAP) Enables the Manipulation of Mitochondrial DNA Levels.

Angew Chem Int Ed Engl

September 2025

Department of Chemistry, University of California, Riverside, 900 University Avenue, Riverside, California, 92521, USA.

Mitochondrial DNA (mtDNA) encodes essential genes for mitochondrial and cellular functions and acts as a cell signaling molecule in innate immune and inflammatory responses. Defects in mtDNA are implicated in a range of mitochondrial disorders and human diseases. Currently, no chemical strategy exists to prevent mtDNA loss under genotoxic stress.

View Article and Find Full Text PDF

The interaction between abasic (apurinic/apyrimidinic, AP) sites and aberrant uracil DNA glycosylase (UDG) contributes to cancer progression, establishing AP site recognition and UDG detection as critical tools for bioanalytical applications and clinical diagnostics. However, existing methods face challenges in achieving high sensitivity and specificity. In this work, we developed DNA-R5, a novel DNA adduct formed by conjugating AP sites with polyarginine-5 (R5), which generates distinctive current signatures in nanopore sensing.

View Article and Find Full Text PDF